Last reviewed · How we verify
Mepolizumab Injection [Nucala]
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues.
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).
At a glance
| Generic name | Mepolizumab Injection [Nucala] |
|---|---|
| Also known as | Anti-IL5 treatment |
| Sponsor | KU Leuven |
| Drug class | IL-5 antagonist monoclonal antibody |
| Target | IL-5 (Interleukin-5) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
IL-5 is a key cytokine that promotes eosinophil development, recruitment, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven diseases such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)
Common side effects
- Headache
- Injection site reaction
- Back pain
- Fatigue
- Nasopharyngitis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepolizumab Injection [Nucala] CI brief — competitive landscape report
- Mepolizumab Injection [Nucala] updates RSS · CI watch RSS
- KU Leuven portfolio CI